Biological effects of 18F-FDG administration and CT dose during PET/CT: chromosomal aberrations in a two-center prospective observational study - Scorecard - MDSpire

Biological effects of 18F-FDG administration and CT dose during PET/CT: chromosomal aberrations in a two-center prospective observational study

  • By

  • Yuri Kawashima

  • Yasuha Kinugasa

  • Mana Ishibashi

  • Wataru Fukumoto

  • Yoshihiro Miyata

  • Reiko Ideguchi

  • Chiemi Sakai

  • Mari Ishida

  • Seiko Hirota

  • Shinji Yoshinaga

  • Ikuno Nishibuchi

  • Yuji Murakami

  • Gloriamaris Loy-Caraos

  • Namkhai Bayasgalan

  • Suvd Bayarjargal

  • Lin Shi

  • Jiying Sun

  • Yasunori Horikoshi

  • Morihito Okada

  • Yuko Nakamura

  • Kazuo Awai

  • Takashi Kudo

  • Satoshi Tashiro

  • July 17, 2026

Share

Clinical Scorecard: Impact of 18F-FDG Administration and CT Radiation Exposure on Chromosomal Aberrations: Findings from a Prospective Observational Study Across Two Centers

At a Glance

CategoryDetail
Condition18F-fluorodeoxyglucose (FDG)-PET/CT Imaging
Key MechanismsAssessment of chromosomal aberrations as biomarkers of radiation exposure and cancer risk.
Target PopulationPatients undergoing clinically indicated FDG-PET/CT for oncologic evaluation.
Care SettingProspective observational study in two hospitals.

Key Highlights

  • Study compares reduced-dose and standard-dose CT protocols in FDG-PET/CT.
  • Chromosomal aberrations (CAs) serve as biomarkers for evaluating radiation effects.
  • Findings support the biological superiority of low-dose CT protocols.

Guideline-Based Recommendations

Diagnosis

  • FDG-PET/CT is used for cancer detection and evaluation.

Management

  • Adhere to the ALARA principle for radiation exposure during imaging.

Monitoring & Follow-up

  • Measure chromosomal aberrations to assess biological effects of radiation.

Risks

  • Increased cancer risk associated with medical imaging radiation exposure.

Patient & Prescribing Data

Patients with suspected malignancies undergoing FDG-PET/CT.

FDG administration does not amplify DNA damage in PET/MRI.

Clinical Best Practices

  • Utilize reduced-dose CT protocols when possible to minimize radiation exposure.
  • Informed consent should include discussions about radiation-related risks.

Related Resources & Content

Original Source(s)

Biological effects of 18F-FDG administration and CT dose during PET/CT: chromosomal aberrations in a two-center prospective observational study

  • by Yuri Kawashima, Yasuha Kinugasa, Mana Ishibashi, Wataru Fukumoto, Yoshihiro Miyata, Reiko Ideguchi, Chiemi Sakai, Mari Ishida, Seiko Hirota, Shinji Yoshinaga, Ikuno Nishibuchi, Yuji Murakami, Gloriamaris Loy-Caraos, Namkhai Bayasgalan, Suvd Bayarjargal, Lin Shi, Jiying Sun, Yasunori Horikoshi, Morihito Okada, Yuko Nakamura, Kazuo Awai, Takashi Kudo, Satoshi Tashiro

  • July 17, 2026

Related Content

CRISPR/Cas9 in cancer therapy: clinical translation, mechanistic strategies, and therapeutic directions

A machine learning-based prognostic model for de novo metastatic HR-positive breast cancer: SEER cohort with external validation

Mass Spec Roundup: Signals Recovered

This week’s stories span amino-metabolite imaging, site-specific HDX-MS, large-scale motif annotation, and proteomics missing-value recovery

  • July 15, 2026

  • 7 min